In the suit, Celmatix claims 23andMe breached its original contract, causing Celmatix financial setbacks.
The two first began talking about exploring women’s fertility in 2015. In the deal, Celmatix offered to pay 23andMe for access to its data and research support. Additionally, the two companies signed an exclusive agreement indicating that 23andMe would not work with competitors in the fertility and infertility space for 10 years.
Celmatix alleges that 23andMe realized the potential of the women’s fertility market and its revenue opportunities. It was then that 23andMe CEO Anne Wojcicki allegedly told her team to make the deal with Celmatix “go away.”
In 2018, the two companies had terminated their agreement and its exclusivity clause. Since then, Celmatix has had to lay off employees and suspend operations. Additionally, the company has stopped working on its fertility test.
23andMe does not comment on pending litigation, a spokesperson told CNBC.
More articles on consumerism:
Google, Uber alums round out executive team of Optum- and Bezos-backed virtual mental health app
Rutgers, Microsoft develop mobile app to reduce SIDS risk
BCBS report finds consumers still prefer in-person healthcare interactions to digital services: 4 notes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
